Press Release

Cooley Continues to Lead the Pack with Recent String of Life Sciences IPOs

Thirteen IPOs in this life-changing innovation space since June
September 17, 2018

Palo Alto – September 17, 2018 – Since June, Cooley has continued its leadership role in the life sciences IPO space, representing companies and underwriters on 13 IPOs during that short time frame. According to data from IPO Vital Signs, Cooley is the #1 law firm advising on issuer- and underwriter-side life sciences IPOs for Q2 2018.

“The momentum in the life sciences capital markets sector continues to be incredible,” said partner David Peinsipp, co-chair of Cooley’s capital markets practice alongside partner Charlie Kim, “and the pace has not slowed a bit heading into the end of the summer.” 

“Our teams continue to fire on all cylinders, partnering with these innovative companies and the investment banks advising them as they go public,” said Kim. “It truly is an exciting time to be working in a sector in which so much game-changing innovation is taking place.”

The deals include:

  • MeiraGTx’s $75 million IPO – Partners Brent Siler and Div Gupta led the team advising the underwriters

  • Crinetics Pharmaceuticals’ $117 million IPO – Partners Charlie Kim, Sean Clayton and Dave Peinsipp led the team advising the underwriters

  • Verrica Pharmaceuticals’ $86 million IPO – Partners Div Gupta, Darren DeStefano and Brent Siler led the team advising the company

  • Eidos Therapeutics’ $122 million IPO – Partners Dave Peinsipp, Div Gupta and Charlie Kim led the team advising the underwriters

  • Kezar Life Sciences’ $86 million IPO – Partners Laura Berezin and Rob Phillips led the team advising the company

  • Forty Seven’s $113 million IPO – Partners Eric Jensen and John McKenna led the team advising the company

  • Translate Bio’s $122 Million IPO – Partners Div Gupta, Josh Kaufman and Nicole Brookshire led the team advising the underwriters

  • Tricida’s $256 million IPO – Partners Dave Peinsipp, Div Gupta and Charlie Kim led the team advising the underwriters

  • Neon Therapeutics’ $100 million IPO – Partners Div Gupta, Charlie Kim and Nicole Brookshire led the team advising the underwriters

  • Neuronetics’ $108 Million IPO – Partners Div Gupta, Josh Kaufman and Jeff Libson led the team advising the company

  • Liquidia’s $53 million IPO – Partners Brent Siler, Brian Leaf and Div Gupta led the Cooley team advising the underwriters

  • Aquestive’s $74 million IPO – Partners Daniel Goldberg, Ryan Sansom and Div Gupta led the Cooley team advising the underwriters

  • Aridis Pharmaceuticals’ $26 million IPO – Partners David Peinsipp, Charlie Kim and Drew Williamson led the Cooley team advising the underwriters

According to IPO Vital Signs and PitchBook data, Cooley is the #1 law firm for VC-backed IPOs across all industries over the last 10 years. Additionally, in 2017, Cooley ranked #1 for issuer-side IPOs across all industries, #1 for VC-backed IPOs across all industries, and #1 for all tech & life sciences IPOs. In 2017, Cooley advised on 136 completed capital markets transactions, including 30 IPOs. Moreover, Cooley is one of the top firms working on capital markets transactions for non-US private issuers.

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law. 

Cooley has 900+ lawyers across 13 offices in the United States, China and Europe.

 

This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as “Cooley”). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. This content may be considered Attorney Advertising and is subject to our legal notices.